Microdevice for Psoriasis and Atopic Dermatitis

This trial tests a new microdevice designed to treat skin conditions such as eczema and psoriasis. The device, about the size of a grain of rice, releases small amounts of FDA-approved medications directly into the skin. Researchers aim to determine if this in situ cutaneous microdevice can safely predict skin responses to standard treatments and explore connections to genetic information. This trial may suit adults managing eczema or psoriasis. As a Phase 4 trial, the treatment has already received FDA approval and proven effective, providing an opportunity to understand its benefits for more patients.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research shows that the small device used in this study aims to be safe and effective for skin conditions like eczema and psoriasis. It applies tiny amounts of FDA-approved medications directly to the skin, using much smaller doses than usual treatments.

Since these medications are already approved for these skin conditions, they are generally safe when used correctly. However, the device itself is new, and researchers are testing it to ensure it is safe and can accurately show how the skin will react to these treatments.

Researchers are excited about the in situ cutaneous microdevice for psoriasis and atopic dermatitis because it offers a novel way to deliver medication directly into the skin. Unlike traditional treatments like topical creams or systemic medications, this tiny device, about the size of a grain of rice, releases very small amounts of FDA-approved drugs directly where they are needed. This targeted delivery method could reduce side effects by using much lower doses than standard treatments. Additionally, the device may help predict individual skin responses to treatments, potentially personalizing therapy based on genetic information and improving overall results.

Research shows that the in situ cutaneous microdevice, which participants in this trial will receive, is being tested to determine if it can safely and effectively predict responses of skin conditions like eczema and psoriasis to standard treatments. The device releases tiny amounts of FDA-approved medications for these conditions directly into the skin. This method uses much lower doses of medication than usual, which might reveal how well these treatments work. Early results suggest that the device can measure reactions of skin lesions to these medications. The goal is to determine if these reactions can predict overall treatment success, potentially leading to more personalized treatment plans in the future.¹³⁵⁶⁷